The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials

被引：0
|
作者：
Chongzhen Guo
Chengda Yan
Lianyue Qu
Rongrong Du
Jianyang Lin
机构：
[1] The First Hospital of China Medical University,Department of Pharmacy
[2] China Medical University,School of Pharmaceutical Science
来源：
Archives of Gynecology and Obstetrics | 2021年 / 303卷
关键词：
Angiogenesis inhibitors; Ovarian cancer; Progression-free survival; Overall survival; Toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：285 / 311
页数：26
相关论文
共 50 条
  • [1] The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials
    Guo, Chongzhen
    Yan, Chengda
    Qu, Lianyue
    Du, Rongrong
    Lin, Jianyang
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 303 (02) : 285 - 311
  • [2] Does the age affect the efficacy of angiogenesis inhibitors in ovarian cancer? A meta-analysis of randomized controlled trials
    Miao, H.
    Miao, C-X
    Han, J.
    Li, N.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (13) : 3047 - 3053
  • [3] Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials
    Li, Xuyuan
    Zhu, Sujuan
    Hong, Chaoqun
    Cai, Haoquan
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (03) : 555 - 562
  • [4] Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials
    Wang, Haihong
    Xu, Tie
    Zheng, Lifen
    Li, Guiling
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (05) : 903 - 914
  • [5] Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials
    Fu, Xue-Lei
    Feng, Li-Ping
    Yu, Hai-Rong
    Du, Lin
    Song, Yi-Ping
    Chen, Hong-Lin
    MELANOMA RESEARCH, 2022, 32 (03) : 159 - 165
  • [6] Adverse events risk associated with angiogenesis inhibitors addition to therapy in ovarian cancer: a meta-analysis of randomized controlled trials
    Liang, X. -J.
    Shen, J.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (12) : 2701 - 2709
  • [7] Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials
    Shao, Fengping
    Liu, Jun
    Duan, Yaoyun
    Li, Li
    Liu, Liqun
    Zhang, Cai
    He, Shanyang
    BIOSCIENCE REPORTS, 2020, 40
  • [8] Efficacy of niraparib in patients with advanced ovarian cancer: A meta-analysis of randomized controlled trials
    Marinho, Alice
    Fossen, Eduardo Lambert
    Caldeira de Freitas, Maria Carolina
    Itaya, Gabriela Coelho
    Da Costa, Larissa Maria
    Dias, Yasmin
    Goncalves Celso, Davi Said
    Dos Santos, Marcela Bonalumi
    De Souza, Mariana
    Vilbert, Maysa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta-analysis
    Zhang, Chunmei
    Zhao, Wancheng
    JOURNAL OF OVARIAN RESEARCH, 2022, 15 (01)
  • [10] The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trials
    Zhang, Jian
    Liu, Jie
    Chen, Huiguo
    Wu, Weibin
    Li, Xiaojun
    Wu, Yonghui
    Zhang, Kai
    Gu, Lijia
    ONCOTARGETS AND THERAPY, 2015, 8 : 2375 - 2382
12345